AbbVie stock hits fresh 52-week high as earnings strength and guidance lift outlook
Published on 08/20/2026 at 10:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock pushed to a new 52-week high of $265.97 on August 19, 2026, as investors reacted to stronger-than-expected quarterly results and firmer guidance for the rest of the year. Per recent market data, the shares closed the August 19, 2026 session at $265.63, up 2.6% for the day.
Earnings beat and revenue growth back the move
Fresh coverage of AbbVie’s latest quarterly report highlights that the company delivered earnings per share of $3.65 in its most recent quarter, topping the consensus estimate of $3.61 by $0.04. A detailed post-earnings summary notes that revenue for the quarter reached $16.99 billion, ahead of analyst expectations of $16.80 billion.
That same report indicates that AbbVie’s quarterly revenue rose 10.2% year over year, underscoring that the company is again posting double-digit top-line growth after absorbing past patent expirations. The comparison is also visible on the earnings line, with EPS of $3.65 compared with $2.97 in the same quarter a year earlier.
Profitability metrics in the latest quarter were mixed, with the company generating a reported net margin of 9.80% while also showing an unusually high negative return on equity of 422.07%, reflecting the impact of its capital structure and past acquisitions. Even so, cash returns to shareholders remain meaningful, with an annualized dividend of $6.92 per share that currently equates to a yield of 2.6% on the recent share price.
Guidance raised and valuation context
Looking ahead, AbbVie has issued guidance for the next quarter that calls for EPS in a range of $3.84 to $3.88, signaling management’s confidence that earnings will continue to grow from the latest reported $3.65 per share. The same set of estimates suggests that sell-side analysts currently expect AbbVie to deliver $14.07 in EPS for the full current year, implying that the stock is trading on a forward multiple that bakes in further profit expansion.
Technical and valuation-focused commentary points out that AbbVie stock is trading above both its 50-day and 200-day moving averages, indicating an established uptrend. According to a recent breakdown of trading data, the shares have a 50-day moving average price of $246.17 and a 200-day moving average price of $226.63, so the latest close at $265.63 places the stock roughly $19 above its short-term trend line and almost $39 above its longer-term average.
The broader performance backdrop supports that picture. One recent analysis notes that AbbVie stock has returned 24.5% over the trailing three months, significantly outpacing a 3.9% gain for the S&P 500 over the same span. A breakout-focused review describes the shares as trading near the top of their 52-week range with momentum concentrated in key growth franchises.
Income investors are also watching the dividend profile as the stock climbs. A separate feature on institutional positioning highlights that AbbVie’s dividend has risen more than 330% since the company’s spinoff from Abbott in 2013, underscoring its track record as a mature cash-return story even as it invests in new therapies. That piece on institutional interest notes that one large hedge fund recently added significantly to its position, citing the combination of yield and pipeline-driven growth.
Debt funding and long-term growth plans
Beyond quarterly numbers, AbbVie’s capital allocation strategy is also shaping the investment narrative. A recent markets report details how the company has raised $9 billion in new debt to fund an acquisition, reflecting a continued push to diversify its portfolio and extend growth beyond its legacy blockbuster drugs. The coverage of the $9 billion debt deal also references a fresh Buy rating with a $300 price target on the stock, suggesting that some analysts see additional upside from current levels.
Longer-horizon guidance provides a sense of how AbbVie expects its portfolio to evolve. According to a recent strategy-focused analysis, management now guides revenue from one of its key growth drivers, the immunology drug Skyrizi, to $21.7 billion for 2026. The same discussion notes that total company revenue guidance for 2026 has been raised twice this year by a cumulative $600 million, with Skyrizi’s own forecast increased at each step.
Those figures underscore how important immunology and other next-generation therapies are for AbbVie’s trajectory as it works to offset erosion from older products. With the stock trading just below recent highs and guidance moving higher, valuation debate is intensifying, but the earnings and revenue momentum reported in the most recent quarter are central to the bull case.
Skyrizi anchors AbbVie’s growth story
While AbbVie operates across several therapeutic areas, the immunology franchise and particularly Skyrizi has become a bellwether product for investors tracking the company’s progress. The recent strategy commentary that lifts 2026 Skyrizi revenue guidance to $21.7 billion also frames that drug as a central pillar of AbbVie’s efforts to drive durable growth through innovative treatments for conditions such as psoriasis and Crohn’s disease.
In practice, that means Skyrizi’s uptake and market share gains are watched closely each quarter. As total company revenue for 2026 is now guided to be $67.6 billion, the projected $21.7 billion contribution from Skyrizi alone would represent almost one-third of AbbVie’s expected top line, illustrating how concentrated the growth engine has become around that single brand. Each upward revision to Skyrizi’s outlook therefore has an outsized impact on the company’s medium-term revenue and earnings path.
For retail investors, the Skyrizi story offers a concrete way to think about AbbVie’s pipeline risk and opportunity. Stronger-than-expected adoption would help justify the valuation implied by a stock price in the mid-$260s, while any setback in the drug’s competitive positioning or safety profile would likely weigh on both guidance and sentiment, given how much of the 2026 revenue plan depends on it.
AbbVie stock at a new high
From a trading perspective, the key price markers give a sense of where AbbVie stock now stands. One detailed quote page shows a last price of $265.69 for AbbVie shares, with the close on August 19, 2026 reported at $265.69, up 2.62% on the day as the regular session ended at 4:00 p.m. ET. That quote snapshot reinforces the picture of a stock that has broken out to the upper end of its one-year trading range.
Complementary technical data describe AbbVie’s 52-week high at $265.97 as of August 19, 2026, with the shares clearing a previous late-July peak and leaving their spring range behind. A recent performance card highlights that new 52-week high, framing the move as part of a multi-month advance supported by improving fundamentals.
Additional technical commentary from another market-data overview lists AbbVie’s stock price at $258.92 on a recent snapshot and categorizes the shares as a Buy based on indicators such as the 8-day simple moving average of $250.30. That technical overview notes that the price trading above key moving averages is a supportive signal for trend-following investors, even as shorter-term overbought readings may encourage some profit-taking.
For now, the combination of a new 52-week high at $265.97, a closing price of $265.63 on August 19, 2026, and consensus full-year EPS expectations of $14.07 captures the essence of the AbbVie story: a large-cap healthcare name that is delivering double-digit revenue growth and lifting guidance, with the market rewarding that execution through a steadily rising share price.
Read more
More on AbbVie stock at the company site
Skyrizi as a flagship immunology product
Among AbbVie’s portfolio, Skyrizi stands out as a flagship immunology product that illustrates the company’s approach to addressing chronic inflammatory diseases. The drug is approved for multiple indications, including certain forms of psoriasis and inflammatory bowel disease, and has been central to AbbVie’s strategy of building a diversified immunology franchise that can support revenue growth through 2026 and beyond.
By targeting specific components of the immune system, Skyrizi aims to provide durable symptom relief with a dosing schedule designed to be convenient for patients, which has helped drive adoption in competitive markets. As AbbVie’s management lifts Skyrizi’s 2026 revenue guidance to $21.7 billion, the product’s success is increasingly intertwined with the company’s ability to meet or exceed its long-term financial targets.
Current trading snapshot for AbbVie shares
Based on the latest available quote data, AbbVie stock last traded at $265.69 on the New York Stock Exchange as of the close on August 19, 2026, with a daily gain of 2.62% that helped push the shares to a fresh 52-week high of $265.97 earlier in the session. That price level leaves AbbVie trading well above its 50-day moving average of $246.17 and its 200-day moving average of $226.63, underlining the strength of the current uptrend without relying on extreme short-term swings.
Fact box
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Price (as of August 19, 2026, 4:00 p.m. ET): $265.69 USD
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
